Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

ARS Pharmaceuticals (SPRY) Equity Average: 2021-2025

Historic Equity Average for ARS Pharmaceuticals (SPRY) over the last 5 years, with Sep 2025 value amounting to $170.0 million.

  • ARS Pharmaceuticals' Equity Average fell 18.32% to $170.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $170.0 million, marking a year-over-year decrease of 18.32%. This contributed to the annual value of $243.8 million for FY2024, which is 3.19% down from last year.
  • Latest data reveals that ARS Pharmaceuticals reported Equity Average of $170.0 million as of Q3 2025, which was down 19.30% from $210.6 million recorded in Q2 2025.
  • In the past 5 years, ARS Pharmaceuticals' Equity Average ranged from a high of $359.1 million in Q2 2021 and a low of $131.0 million during Q1 2022.
  • Its 3-year average for Equity Average is $227.8 million, with a median of $228.9 million in 2024.
  • Per our database at Business Quant, ARS Pharmaceuticals' Equity Average dropped by 20.35% in 2022 and then skyrocketed by 103.86% in 2023.
  • Quarterly analysis of 5 years shows ARS Pharmaceuticals' Equity Average stood at $150.4 million in 2021, then skyrocketed by 79.47% to $270.0 million in 2022, then fell by 13.32% to $234.0 million in 2023, then declined by 2.19% to $228.9 million in 2024, then decreased by 18.32% to $170.0 million in 2025.
  • Its Equity Average was $170.0 million in Q3 2025, compared to $210.6 million in Q2 2025 and $242.9 million in Q1 2025.